Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization

Acta Ophthalmologica

Volumn 87, Issue 6, 2009, Pages 653-658

  You, In Cheon ^a,b   Kang, In Seong ^b   Lee, Seung Hyun ^b   Yoon, Kyung Chul ^a,c  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

Author keywords

Bevacizumab; Corneal neovascularization; Dose; Subconjunctival injection

Indexed keywords

BEVACIZUMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EYEGLASSES; FEMALE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 69449103378     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01399.x     Document Type: Article

References (30)

1. Avery RL (2006 Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 : 352 354.
2. Awadein A (2007 Subconjunctival bevacizumab for vascularised rejected corneal grafts. J Cataract Refract Surg 33 : 1991 1993.
3. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP Noureddin BN (2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 : 1 9.
4. Batar I, Kaiserman I, McAllum P, Rootman D Slomovic A (2008 Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27 : 142 147.
5. Chang JH, Gabison EE, Kato T Azar DT (2001 Corneal neovascularization. Curr Opin Ophthalmol 12 : 242 249.
6. Corrent G, Roussel TJ, Tseng SC Watson BD (1989 Promation of graft survival by photothrombotic occlusion of corneal neovascularization. Arch Ophthalmol 107 : 1501 1506.
7. D'Amato RJ, Loughnan MS, Flynn E Folkman J (1994 Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 : 4082 4085.
8. DeStafeno JJ Kim T (2007 Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125 : 834 836.
9. Erdurmus M Totan Y (2007 Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245 : 1577 1579.
10. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A Noori F (2007 Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 35 : 745 748.
11. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S Sarra GM (2006 Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 : 1054 1056.
12. Joussen AM, Kruse FE, Völcker HE Kirchhof B (1999 Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237 : 920 927.
13. Kernt M, Neubauer AS Kampik A (2007 Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85 : 119 120. (Pubitemid 46140172)
14. Lepri A, Benelli U, Bernardini N, Bianchi F, Lupetti M, Danesi R, Del Tacca M Nardi M (1994 Effect of low molecular weight heparin surfate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 10 : 273 280.
15. Lipman RM, Epstein RJ Hendricks RL (1992 Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 10 : 405 407.
16. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC Chévez-Barrios P (2007 Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91 : 804 807.
17. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN Venkatraman AS (2005 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 : 1035 1047.
18. Mulcahy MF Benson AB III. (2005 Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5 : 997 1005.
19. O'Reilly MS, Holmgren L, Shing Y et al. (1994 Angiogstatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 : 315 328.
20. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ Vergados IA (2008 Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145 : 424 431.
21. Phillips K, Arffa R, Cintron C, Rose J, Miller D, Kublin CL Kenyon KR (1983 Effect of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 30 : 1588 1593.
22. Pillai CT, Dua HS Hossain P (2000 Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 41 : 2148 2153.
23. Plate KH, Breier G, Welch HA Risau W (1992 Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359 : 845 848.
24. Risau W (1997 Mechanisms of angiogenesis. Nature 386 : 671 674.
25. Rosenfeld PJ, Fung AE Puliafito CA (2005 Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 : 336 339.
26. Verbey NL, van Haeringen NJ de Jong PT (1988 Modulation of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase. Curr Eye Res 7 : 361 368.
27. Yancopoulos G, Klagsbrun M Folkman J (1998 Vasculogenesis, angiogenesis, and growth factor: ephrins enter the fray at the border. Cell 93 : 661 664.
28. Yao Y, Guan M, Zhao XQ Huang YF (2003 Downregulation of the pigment epithelial derived factor by hypoxia and elevated glucose concentration in cultured human retinal pigment epithelial cells. Zhonghua Yi Xue Za Zhi 25 : 1989 1992.
29. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU Szurman P Tübingen bevacizumab study group (2008 Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 86 : 322 328.
30. Yoon KC, You IC, Kang IS, Im SK, Ahn JK, Park YG Ahn KY (2007 Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol 144 : 390 395.